This meeting took place in 2016



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Modern Phenotypic Drug Discovery: Defining the Path Forward (D1)


Organizer(s) Jonathan A. Lee, Ellen L. Berg and Eugene C. Butcher
April 2—6, 2016
Big Sky Resort • Big Sky, Montana USA
Discounted Abstract Deadline: Dec 2, 2015
Abstract Deadline: Jan 5, 2016
Scholarship Deadline: Dec 2, 2015
Discounted Registration Deadline: Feb 2, 2016

Sponsored by Abide Therapeutics Inc., Janssen R&D: Pharmaceutical Companies of Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited and Vertex Pharmaceuticals Incorporated

Summary of Meeting:
Innovation and productivity in pharmaceutical drug discovery have been below expectations. Surprisingly, more first-in-class small molecule drugs approved by the FDA (1999-2008) were identified by functional approaches reminiscent of pre-genomics pharmacology (phenotypic drug discovery) than by contemporary molecular targeted strategies. This observation, and the unexpected difficulties of target validation, have diminished the impact of the “genomics revolution” and are arguably associated with the decline in innovation and productivity of pharmaceutical research. As a result, pharmaceutical researchers have begun to reevaluate the “Molecular Mindset” which has dominated our collective drug-hunting culture, and explore modern approaches to phenotypic screening. However, there is currently no single scientific forum where scientists from pharma, biotech, academia and instrument/service providers can meet and discuss strategies/issues related to phenotypic drug discovery (PDD). In part, this is because PDD encompasses multiple therapeutic areas and involves diverse disciplines including drug discovery, chemistry, cell biology, stem cell biology, systems biology, genomics, bioengineering and informatics. This Keystone Symposia meeting uniquely provides this interdisciplinary environment and is a particularly attractive venue given the increasing role of academia in drug discovery research. The conference will be a forum for the global PDD research community in which scientists from diverse institutions and scientific disciplines can meet to share/discuss/debate topics related to advantages/disadvantages of PDD and how PDD can complement targeted approaches. Significantly, the conference will provide a much needed forum for the growing interest in PDD, and can conceivably become the cornerstone of the global scientific movement for the reintroduction of functional biology/physiology-driven pharmaceutical research.

View Meeting Program

Scholarships/Awards

National Center for Advancing Translational Sciences (NCATS) Scholarship Recipients

Maria Arvena DeCicco RePass
Tufts Sackler School of Graduate Biomedical Sciences, USA

Scott Warchal
Institute of Genetics and Molecular Medicine, Scotland